---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-006200"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:38:01.316668+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q1 revenue $154.6M (+30% YoY); reaffirms FY2024 guidance $700-720M

## Summary
- Q1 net revenue $154.6M (+30% YoY); GAAP EPS $0.67, adjusted EPS $0.88.
- Reaffirmed FY 2024 net revenue guidance of $700-720M.
- Pipeline: sNDA for pitolisant in IH planned H2 2024; pediatric narcolepsy PDUFA June 21, 2024.
- Licensed TPM-1116 (orexin-2 agonist) for narcolepsy; IND expected mid-2025.
- Acquired Epygenix for rare epilepsy; clemizole Dravet/LGS pivotal trial topline 2026.

## SEC filing metadata
- accession: 0001558370-24-006200
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/0001558370-24-006200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/hrmy-20240430x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-006200
- JSON: https://secwatch.observer/filing/0001558370-24-006200.json
- Plain text: https://secwatch.observer/filing/0001558370-24-006200.txt

## Key facts
- Earnings Releases
  Harmony Biosciences Holdings, Inc. reported Q1 2024 results: revenue WAKIX Net Revenue of $154.6 Million, net income GAAP net income for the quarter ended March 31, 2024, was $38.3 million, EPS $0.67 per diluted share. Guidance reaffirmed.
  - Period: Q1 2024
  - Revenue: WAKIX Net Revenue of $154.6 Million
  - Net income: GAAP net income for the quarter ended March 31, 2024, was $38.3 million
  - EPS: $0.67 per diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: ADVANCES PITOLISANT FRANCHISE TO EXTEND REVENUE POTENTIAL BEYOND 2040; STRENGHTENS SLEEP/WAKE LEADERSHIP AND DIVERSIFIES INTO RARE EPILEPSY ​ WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year ​ Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 ​ On Track Toward
  evidence_url: https://www.sec.gov/Archives/edgar/data/1802665/000155837024006200/0001558370-24-006200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.